Potential Impact of on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score–Matched Analysis
Background: Surgical resection followed by adjuvant chemotherapy is the only therapeutic option in pancreatic cancer. However, there is limited research evaluating methods of improving adherence to adjuvant treatment after curative resection. Methods: From January 1995 to December 2014, 323 patients...
Main Authors: | Sung Hwan Lee MD, PhD, Ho Kyoung Hwang MD, PhD, Chang Moo Kang MD, PhD, Woo Jung Lee MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-02-01
|
Series: | Integrative Cancer Therapies |
Online Access: | https://doi.org/10.1177/1534735418816825 |
Similar Items
-
Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma
by: Qinglin Fei, MD, et al.
Published: (2020-09-01) -
Liver metastases from pancreatic ductal adenocarcinoma: is there a place for surgery in the modern era?
by: Katsunori Imai, MD, PhD, FACS, et al.
Published: (2020-06-01) -
Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study
by: Sung E. Oh MD, et al.
Published: (2021-09-01) -
Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors
by: Luohai Chen, MD, PhD, et al.
Published: (2019-09-01) -
Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a Swedish population-based propensity score-matched analysis
by: Slavica Janeva, MD, et al.
Published: (2020-12-01)